Family Capital Trust Co Invests $1.97 Million in AbbVie Inc. $ABBV

Family Capital Trust Co purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 8,493 shares of the company’s stock, valued at approximately $1,966,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Brighton Jones LLC increased its stake in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in AbbVie in the first quarter worth about $383,000. Acadian Asset Management LLC raised its stake in shares of AbbVie by 5.7% in the first quarter. Acadian Asset Management LLC now owns 142,756 shares of the company’s stock worth $29,898,000 after buying an additional 7,640 shares during the period. Finally, Mattson Financial Services LLC lifted its position in shares of AbbVie by 4.0% during the 1st quarter. Mattson Financial Services LLC now owns 5,211 shares of the company’s stock valued at $1,092,000 after buying an additional 201 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Pipeline/clinical progress — AbbVie advanced its icalcaprant (depression) Phase 2 program, which supports medium‑term pipeline optionality beyond its core immunology/oncology franchises. AbbVie Advances Icalcaprant Trial in Depression: What Investors Should Watch
• Positive Sentiment: Early‑stage oncology expansion — AbbVie launched a first‑in‑human trial for ABBV‑901 in ovarian cancer, increasing optional upside if the program shows early signal. AbbVie Expands Ovarian Cancer Pipeline With New First‑in‑Human ABBV‑901 Trial
• Positive Sentiment: Analyst support — Berenberg issued a buy on ABBV, giving some near‑term credibility to upside narratives and providing a buy signal for income/value investors. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Dividend/income appeal — commentary highlighting AbbVie’s yield and steady dividend profile is keeping income‑focused investors engaged despite valuation premium. AbbVie: The Dividend Does Not Lie
• Neutral Sentiment: Real‑world study readouts — post‑marketing/observational studies for Rinvoq (Korea) and upadacitinib (Japan) wrapped, which may gradually support label expansion and payer confidence but are not immediate revenue catalysts. AbbVie’s Korean Rinvoq Study in IBD Wraps Up, Setting the Stage for New Real‑World Data
• Neutral Sentiment: Upcoming results call — AbbVie set its full‑year and Q4 earnings release and Feb. 4 conference call; investors will watch guidance reconciliation and quarterly details for clarity. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Negative Sentiment: Guidance slightly below consensus — AbbVie trimmed/updated Q4 and FY‑2025 EPS ranges that sit at or just below street consensus, which likely pressured the stock as investors reprice near‑term growth expectations.
• Negative Sentiment: One‑time IPR&D/R&D charges — management flagged IPR&D and related expenses that will negatively impact Q4 EPS, creating near‑term earnings noise ahead of the February print. AbbVie sees negative Q4 EPS impact from IPR&D expenses
• Negative Sentiment: Failed takeover optimism — earlier media reports that AbbVie was in talks to buy Revolution Medicines briefly lifted sentiment; AbbVie subsequently denied talks, prompting disappointment and a reversal in momentum. AbbVie Denies It’s in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $289.00 target price (up from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Citigroup lowered their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Finally, Morgan Stanley raised their price target on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $246.89.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $224.22 on Friday. The company has a market cap of $396.28 billion, a P/E ratio of 169.86, a P/E/G ratio of 0.98 and a beta of 0.36. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The firm’s fifty day moving average is $226.55 and its two-hundred day moving average is $214.86.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the business posted $3.00 earnings per share. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.